These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18498083)

  • 1. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.
    Gopi H; Cocklin S; Pirrone V; McFadden K; Tuzer F; Zentner I; Ajith S; Baxter S; Jawanda N; Krebs FC; Chaiken IM
    J Mol Recognit; 2009; 22(2):169-74. PubMed ID: 18498083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
    Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I
    J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
    Umashankara M; McFadden K; Zentner I; Schön A; Rajagopal S; Tuzer F; Kuriakose SA; Contarino M; Lalonde J; Freire E; Chaiken I
    ChemMedChem; 2010 Nov; 5(11):1871-9. PubMed ID: 20677318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-natural peptide triazole antagonists of HIV-1 envelope gp120.
    Kamanna K; Aneja R; Duffy C; Kubinski P; Rodrigo Moreira D; Bailey LD; McFadden K; Schön A; Holmes A; Tuzer F; Contarino M; Freire E; Chaiken IM
    ChemMedChem; 2013 Feb; 8(2):322-8. PubMed ID: 23239505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.
    Rosemary Bastian A; Nangarlia A; Bailey LD; Holmes A; Kalyana Sundaram RV; Ang C; Moreira DR; Freedman K; Duffy C; Contarino M; Abrams C; Root M; Chaiken I
    J Biol Chem; 2015 Jan; 290(1):529-43. PubMed ID: 25371202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy.
    Emileh A; Duffy C; Holmes AP; Rosemary Bastian A; Aneja R; Tuzer F; Rajagopal S; Li H; Abrams CF; Chaiken IM
    Biochemistry; 2014 Jun; 53(21):3403-14. PubMed ID: 24801282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.
    Tuzer F; Madani N; Kamanna K; Zentner I; LaLonde J; Holmes A; Upton E; Rajagopal S; McFadden K; Contarino M; Sodroski J; Chaiken I
    Proteins; 2013 Feb; 81(2):271-90. PubMed ID: 23011758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
    Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
    Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.
    McFadden K; Fletcher P; Rossi F; Kantharaju ; Umashankara M; Pirrone V; Rajagopal S; Gopi H; Krebs FC; Martin-Garcia J; Shattock RJ; Chaiken I
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1073-80. PubMed ID: 22083481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide triazole inactivators of HIV-1: how do they work and what is their potential?
    Chaiken I; Rashad AA
    Future Med Chem; 2015; 7(17):2305-10. PubMed ID: 26599515
    [No Abstract]   [Full Text] [Related]  

  • 12. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.
    Grupping K; Selhorst P; Michiels J; Vereecken K; Heyndrickx L; Kessler P; Vanham G; Martin L; Ariën KK
    Retrovirology; 2012 May; 9():36. PubMed ID: 22551420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
    Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
    Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.
    Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV
    PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.
    Rashad AA; Acharya K; Haftl A; Aneja R; Dick A; Holmes AP; Chaiken I
    Org Biomol Chem; 2017 Sep; 15(37):7770-7782. PubMed ID: 28770939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein.
    Morellato-Castillo L; Acharya P; Combes O; Michiels J; Descours A; Ramos OH; Yang Y; Vanham G; Ariën KK; Kwong PD; Martin L; Kessler P
    J Med Chem; 2013 Jun; 56(12):5033-47. PubMed ID: 23710622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.
    Cocklin S; Gopi H; Querido B; Nimmagadda M; Kuriakose S; Cicala C; Ajith S; Baxter S; Arthos J; Martín-García J; Chaiken IM
    J Virol; 2007 Apr; 81(7):3645-8. PubMed ID: 17251295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins.
    Anang S; Zhang S; Fritschi C; Chiu T-J; Yang D; Smith Iii AB; Madani N; Sodroski J
    J Virol; 2023 Nov; 97(11):e0117123. PubMed ID: 37888980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.